lumiliximab

{{Short description|Monoclonal antibody}}

{{Drugbox

| Verifiedfields = changed

| Watchedfields = changed

| verifiedrevid = 447732435

| type = mab

| mab_type = mab

| source = xi/i

| target = CD23

| tradename =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category =

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| CAS_number_Ref = {{cascite|changed|??}}

| CAS_number = 357613-86-6

| ATC_prefix = none

| ATC_suffix =

| PubChem =

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank = DB06162

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = 8Z13S29R5A

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = none

| C=2115 | H=3252 | N=556 | O=673 | S=16

}}

Lumiliximab is an IgG1k monoclonal antibody that targets CD23. It acts as an immunomodulator{{cite journal | title = International Nonproprietary Names for Pharmaceutical Substances (INN) | journal = WHO Drug Information | volume = 18 | issue = 3 | date = 2004 | url = https://www.who.int/medicines/publications/druginformation/innlists/RL52.pdf?ua=1 }} and was awarded orphan drug status and fast track designation by the FDA.{{cite web | title = Lumiliximab | url = http://adisinsight.springer.com/drugs/800008890 | work = Adis Insight | publisher = Springer Nature Switzerland AG }}

It was investigated in Phase II/III clinical trials for the treatment of chronic lymphocytic leukemia.{{cite journal | vauthors = Byrd JC, Kipps TJ, Flinn IW, Castro J, Lin TS, Wierda W, Heerema N, Woodworth J, Hughes S, Tangri S, Harris S, Wynne D, Molina A, Leigh B, O'Brien S | display-authors = 6 | title = Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia | journal = Blood | volume = 115 | issue = 3 | pages = 489–95 | date = January 2010 | pmid = 19843887 | pmc = 2810983 | doi = 10.1182/blood-2009-08-237727 }}{{ClinicalTrialsGov|NCT00801060|Evaluation of Safety and Efficacy of Fludarabine, Cyclophosphamide, and Rituximab (FCR) +/- Lumiliximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia (CLL)}} It has also been studied for use in allergic asthma. The drug is a chimeric antibody from Macaca irus and Homo sapiens.

Lumiliximab was developed by IDEC Pharmaceuticals, which was acquired by Biogen.

Clinical trials for CLL were terminated in 2010, and for allergic asthma in 2007. Results published from the CLL clinical trial failed to meet primary endpoints.{{cite journal | vauthors = Awan FT, Hillmen P, Hellmann A, Robak T, Hughes SG, Trone D, Shannon M, Flinn IW, Byrd JC | display-authors = 6 | title = A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia | journal = British Journal of Haematology | volume = 167 | issue = 4 | pages = 466–77 | date = November 2014 | pmid = 25130401 | doi = 10.1111/bjh.13061 | s2cid = 25789983 | doi-access = free | hdl = 2318/1577053 | hdl-access = free }}